This site is intended for healthcare professionals only

Diabetes Digest


Share this article

Long-term outcomes of islet cell transplantation

Islet transplantation results in good long-term glycaemic control without severe hypoglycaemia for many recipients.

Previously, two trials from the Clinical Islet Transplantation Consortium demonstrated that islet cell transplantation, either alone or after a kidney transplant, was a safe and effective treatment for people with type 1 diabetes experiencing severe hypoglycaemia, with most participants achieving an HbA1c of <53 mmol/mol in the absence of severe hypoglycaemia (Hering et al, 2016; Markmann et al, 2021). The objective of the present study was to determine islet graft function and outcomes over longer-term follow-up, up to 8 years.

Of the 48 islet-alone and 24 islet-after-kidney transplant recipients, 7 and 9, respectively, experienced islet graft failure over the original or long-term follow-up, while 15 and 7 withdrew from long-term follow-up with islet graft function intact. The remaining 15 and 7, respectively, completed long-term follow-up and had intact islet graft function. Actuarial islet graft survival rates at final follow-up were 69% for islet-alone and 49% for islet-after-kidney transplants.

Overall, 57% and 35% of islet-only and islet-after-kidney recipients maintained an HbA1c of <53 mmol/mol at final follow-up, while over 90% of both cohorts were free from severe hypoglycaemia. Of the 53 participants who achieved good glycaemic control without need for exogenous insulin therapy, 54% of islet-alone and 63% of islet-after-kidney recipients remained insulin-independent throughout the duration of follow-up.

Kidney function remained stable in both cohorts over the follow-up, and rates of sensitisation to islet donor human leukocyte antigen were low. Severe adverse events occurred at rates of 0.31 and 0.43 per person-year in the islet-alone and islet-after-kidney cohorts, respectively.

The authors conclude that islet transplantation results in good long-term glycaemic control without severe hypoglycaemia for many recipients with type 1 diabetes and impaired hypoglycaemia awareness. Glycaemic control and islet graft survival may be superior with islet-alone transplantation; however, this must be balanced against the lower added risk of immunosuppression in people who are already receiving it for a kidney transplant.

Click here to read the study in full.

Related content
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals


By clicking ‘Subscribe’, you are agreeing that are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.